To identify possible early predictors (symptoms and biomarkers) of celiac disease, compare symptoms before and after screening, and evaluate the diagnostic efficacy of serologic screening for celiac disease in an adult Danish population.
This cross-sectional population-based study was based on the 5-year follow-up of the Health2006 cohort, where 2297 individuals were screened for celiac disease; 56 were antibody positive and thus invited to clinical evaluation. Eight were diagnosed with biopsy-verified celiac disease. A follow-up questionnaire was sent to antibody-positive individuals 19 months after the clinical evaluation to obtain information on their symptoms and their experience with participation in the screening.
Before screening, participants subsequently diagnosed with celiac disease did not differ from the rest of the population with respect to symptoms, but had significantly lower total cholesterol. Tissue transglutaminase IgA antibodies with a cut-off of 10 U/ml had a positive predictive value of 88%. The majority of participants were satisfied with their participation in the screening program. Individuals with celiac disease were generally satisfied with having been diagnosed and 71% felt better on a gluten-free diet.
There were no differences in the prevalence of symptoms between participants with and without screening-detected celiac disease, confirming that risk stratification in a general population by symptoms is difficult. The majority of participants diagnosed with celiac disease felt better on a gluten-free diet despite not reporting abdominal symptoms before diagnosis and participants in the clinical evaluation were generally satisfied with participation in the screening program.
Supplemental Digital Content is available in the text.
aResearch Centre for Prevention and Health, The Capital Region, Glostrup
bQ&D, Research Unit and Department of Gastroenterology, Herlev and Gentofte Hospital
cDepartment of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen
dDepartment of Clinical Experimental Research, Rigshospitalet, Denmark
Correspondence to Line L. Kårhus, MD, Research Centre for Prevention and Health, The Capital Region, Rigshospitalet, Nordre Ringvej 57, Building 84-85, DK-2600 Glostrup, Denmark Tel: +45 38633260; fax: +45 38633977; e-mail: email@example.com
Received April 22, 2016
Accepted June 17, 2016